FR07C0073I1 - - Google Patents

Info

Publication number
FR07C0073I1
FR07C0073I1 FR07C0073C FR07C0073I1 FR 07C0073 I1 FR07C0073 I1 FR 07C0073I1 FR 07C0073 C FR07C0073 C FR 07C0073C FR 07C0073 I1 FR07C0073 I1 FR 07C0073I1
Authority
FR
France
Prior art keywords
antibodies
useful
mimics
diagnosis
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0073(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR07C0073I1 publication Critical patent/FR07C0073I1/fr
Application granted granted Critical
Publication of FR07C0073I2 publication Critical patent/FR07C0073I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR07C0073C 1992-06-25 2007-12-21 Vaccin contre le papillomavirus Active FR07C0073I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90310992A 1992-06-25 1992-06-25
PCT/US1993/006109 WO1994000152A1 (en) 1992-06-25 1993-06-24 Papillomavirus vaccines

Publications (2)

Publication Number Publication Date
FR07C0073I1 true FR07C0073I1 (da) 2008-01-02
FR07C0073I2 FR07C0073I2 (fr) 2012-08-03

Family

ID=25416951

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0073C Active FR07C0073I2 (fr) 1992-06-25 2007-12-21 Vaccin contre le papillomavirus

Country Status (12)

Country Link
US (2) US20020068326A1 (da)
EP (2) EP1835029A1 (da)
AT (1) ATE380871T1 (da)
AU (1) AU697743C (da)
DE (9) DE122007000099I1 (da)
DK (1) DK0647140T3 (da)
ES (1) ES2294778T3 (da)
FR (1) FR07C0073I2 (da)
LU (8) LU91395I2 (da)
NL (8) NL300320I1 (da)
PT (1) PT647140E (da)
WO (1) WO1994000152A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE234925T1 (de) 1991-07-19 2003-04-15 Univ Queensland Impfstoffe gegen papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
AU693203B2 (en) * 1994-05-16 1998-06-25 Merck Sharp & Dohme Corp. Papillomavirus vaccines
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
JPH10506014A (ja) * 1994-09-22 1998-06-16 メルク エンド カンパニー インコーポレーテッド ヒトパピローマウイルス６ａ型をコードするＤＮＡ
CA2202090C (en) 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
AU755679B2 (en) * 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU4971099A (en) * 1998-07-13 2000-02-01 Loyola University Of Chicago Papillomavirus cellular receptor
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
TR200101055T2 (tr) * 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK2068918T3 (da) 2006-09-26 2012-07-30 Infectious Disease Res Inst Vaccinesammensætning omfattende syntetisk adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
EP2280728B1 (en) 2008-05-26 2016-03-02 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (en) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
RU2560182C2 (ru) 2009-06-05 2015-08-20 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP2556377B1 (en) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
TR201908003T4 (tr) 2012-02-07 2019-06-21 Infectious Disease Res Inst TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
IL298227B1 (en) 2016-06-01 2024-05-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
CN111315362A (zh) 2017-06-15 2020-06-19 传染病研究所 纳米结构脂质载剂和稳定乳剂以及其用途
KR20200066309A (ko) 2017-09-08 2020-06-09 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 사포닌을 포함하는 리포솜 제형 및 사용 방법
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4455296A (en) * 1982-02-02 1984-06-19 Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) * 1984-09-11 1986-06-24 Merck & Co., Inc. Immunogenic HAV peptides
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (en) * 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
KR910016343A (ko) * 1990-03-20 1991-11-05 스타인, 부그 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
ATE234925T1 (de) * 1991-07-19 2003-04-15 Univ Queensland Impfstoffe gegen papillomavirus

Also Published As

Publication number Publication date
NL300318I2 (nl) 2008-03-03
DE122007000096I1 (de) 2008-03-27
DK0647140T3 (da) 2008-02-04
DE122007000099I1 (de) 2008-03-27
LU91397I2 (fr) 2008-02-14
NL300315I2 (nl) 2008-03-03
ES2294778T3 (es) 2008-04-01
LU91395I2 (fr) 2008-02-14
LU91393I2 (fr) 2008-02-14
NL300315I1 (nl) 2008-02-01
EP0647140B1 (en) 2007-12-12
DE122007000098I1 (de) 2008-03-27
DE122007000101I1 (de) 2008-03-27
EP0647140A4 (en) 1997-03-19
NL300322I1 (nl) 2008-03-03
ATE380871T1 (de) 2007-12-15
NL300317I1 (nl) 2008-02-01
PT647140E (pt) 2007-12-27
AU697743B2 (en) 1998-10-15
DE122007000097I1 (de) 2008-03-27
NL300320I1 (nl) 2008-03-03
NL300318I1 (nl) 2008-02-01
FR07C0073I2 (fr) 2012-08-03
US8012679B1 (en) 2011-09-06
DE122007000095I1 (de) 2008-03-27
LU91398I2 (fr) 2008-02-14
LU91399I2 (fr) 2008-02-14
US20020068326A1 (en) 2002-06-06
NL300321I1 (nl) 2008-03-03
NL300316I1 (nl) 2008-02-01
DE69334192T2 (de) 2008-12-04
DE122007000094I1 (de) 2008-03-27
LU91400I2 (fr) 2008-02-14
AU1135295A (en) 1996-02-08
EP0647140A1 (en) 1995-04-12
DE122007000100I1 (de) 2008-03-27
WO1994000152A1 (en) 1994-01-06
LU91396I2 (fr) 2008-02-14
LU91394I2 (fr) 2008-02-14
DE69334192D1 (de) 2008-01-24
NL300319I1 (nl) 2008-03-03
AU697743C (en) 2007-06-14
EP1835029A1 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
FR07C0073I1 (da)
DE122008000010I1 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus-hüllproteine